(Alliance News) - AstraZeneca PLC said on Wednesday new, prolonged follow-up results from the phase three Champion-MG trial showed that Ultomiris demonstrated long-term efficacy in adults with generalised myasthenia gravis. Read More
(Alliance News) - AstraZeneca PLC announced positive results from its Etesian phase IIb trial on Monday, which met its primary and secondary endpoints. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its reversal agent Ondexxya has been fully approved in Japan for reversal of acute major bleeds in some patients. Read More
(Alliance News) - AstraZeneca PLC said on Monday that its Evusheld antibody combination for Covid-19 prevention has been granted marketing authorization in the EU. Read More
(Alliance News) - Stock prices in London are seen opening ever-so slightly higher on Monday in a cautious start to the new week, with markets tracking geopolitical developments and rising Covid-19 cases in China, while also awaiting fresh drivers in a quiet day in the economic calendar. Read More
(Alliance News) - The EU's drug watchdog on Thursday recommended for approval AstraZeneca PLC's Covid-19 prevention cocktail, which can be used for patients with immune system problems or severe reactions to other coronavirus vaccines. Read More
(Alliance News) - The EU's drug watchdog on Thursday recommended for approval AstraZeneca's Covid-19 prevention jab, which can be used for patients with immune system problems or severe reactions to normal vaccines. Read More
(Alliance News) - AstraZeneca PLC on Thursday said that a Phase 3 trial for its immunotherapy Imfinzi did not achieve its primary endpoint in the treatment of patients with locally advanced cervical cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said its Alexion subsidiary has reached a settlement agreement with Roche Holding AG's Chugai Pharmaceutical Co Ltd resolving all patent disputes between the two related to rare blood disease drug Ultomiris. Read More
(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Wednesday said their jointly-developed Lynparza drug reduces the risk of death in a form of breast cancer. Read More
AstraZeneca PLC - Cambridge, England-based drugmaker - Says Lynparza treatment has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, who have already been treated with chemotherapy either before or after surgery. Read More
(Alliance News) - Hutchmed (China) Ltd on Monday said it has received USD15 million from AstraZeneca PLC as start-up activities for Saffron commenced. Read More
(Alliance News) - AstraZeneca PLC said on Tuesday its rare disease group has closed an exclusive global collaboration to develop and commercialise an investigational human monoclonal antibody. Read More
